4-79984831-AG-AGG
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_058172.6(ANTXR2):βc.1073_1074insCβ(p.Ala359CysfsTer13) variant causes a frameshift change. The variant allele was found at a frequency of 0.000126 in 1,605,890 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.00013 ( 0 hom., cov: 31)
Exomes π: 0.00013 ( 0 hom. )
Consequence
ANTXR2
NM_058172.6 frameshift
NM_058172.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.14
Genes affected
ANTXR2 (HGNC:21732): (ANTXR cell adhesion molecule 2) This gene encodes a receptor for anthrax toxin. The protein binds to collagen IV and laminin, suggesting that it may be involved in extracellular matrix adhesion. Mutations in this gene cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 4-79984831-A-AG is Pathogenic according to our data. Variant chr4-79984831-A-AG is described in ClinVar as [Pathogenic]. Clinvar id is 2604.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ANTXR2 | NM_058172.6 | c.1073_1074insC | p.Ala359CysfsTer13 | frameshift_variant | 13/17 | ENST00000403729.7 | NP_477520.2 | |
ANTXR2 | NM_001145794.2 | c.1073_1074insC | p.Ala359CysfsTer13 | frameshift_variant | 13/16 | NP_001139266.1 | ||
ANTXR2 | NM_001286780.2 | c.842_843insC | p.Ala282CysfsTer13 | frameshift_variant | 13/17 | NP_001273709.1 | ||
ANTXR2 | NM_001286781.2 | c.842_843insC | p.Ala282CysfsTer13 | frameshift_variant | 13/17 | NP_001273710.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ANTXR2 | ENST00000403729.7 | c.1073_1074insC | p.Ala359CysfsTer13 | frameshift_variant | 13/17 | 1 | NM_058172.6 | ENSP00000385575 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000132 AC: 20AN: 151712Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
20
AN:
151712
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.000125 AC: 182AN: 1454062Hom.: 0 Cov.: 31 AF XY: 0.000134 AC XY: 97AN XY: 723016
GnomAD4 exome
AF:
AC:
182
AN:
1454062
Hom.:
Cov.:
31
AF XY:
AC XY:
97
AN XY:
723016
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000132 AC: 20AN: 151828Hom.: 0 Cov.: 31 AF XY: 0.000148 AC XY: 11AN XY: 74236
GnomAD4 genome
AF:
AC:
20
AN:
151828
Hom.:
Cov.:
31
AF XY:
AC XY:
11
AN XY:
74236
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hyaline fibromatosis syndrome Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 21, 2022 | Variant summary: ANTXR2 c.1073dupC (p.Ala359CysfsX13) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have not been observed at our laboratory but reported in the HGMD database. The variant allele was found at a frequency of 0.0004 in 240676 control chromosomes in the gnomAD database, including 1 homozygote. This frequency is not significantly higher than estimated for a pathogenic variant in ANTXR2 causing Hyaline Fibromatosis Syndrome (0.0004 vs 0.0011), allowing no conclusion about variant significance. c.1073dupC has been reported in the literature as homozgygous and compound heterozygous genotypes in individuals affected with Hyaline Fibromatosis Syndrome (example, PMID 15725249, 12973667, 26335786). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2012 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | Jan 12, 2017 | This frameshifting variant is predicted to truncate the ANTXR2 protein by approximately 25%. This variant is well reported in HFS, as a review of the literature revealed at least four compound heterozygotes, and three homozygotes with HFS carried the variant (PMID: 14508707, 21328543, 22383261, 23554269, 26207694, 26335786, 27174544). Additionally, functional studies by Yan et al. revealed that patient fibroblasts with the p.Ala359CysfsTer13 variant had decreased mRNA levels and abnormalities in protein folding (PMID: 23554269). The highest reported allele frequency is 0.00382 in the European (Non-Finnish) population, and one homozygote was found in the African population according to the ExAC database. The allele frequency is higher than predicted based on disease prevalence, and the presence of a homozygote may contradict evidence for pathogenicity. However, based on the combined evidence of reported cases and functional studies, the variant is classified as likely pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Undiagnosed Diseases Network, NIH | Jun 03, 2016 | This individual has been reported in PMCID: PMC5851806 (individual 1). - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 18, 2023 | This sequence change creates a premature translational stop signal (p.Ala359Cysfs*13) in the ANTXR2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ANTXR2 are known to be pathogenic (PMID: 12973667, 14508707). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with infantile systemic hyalinosis (PMID: 14508707, 28914269). This variant is also known as 1601-1602insC. ClinVar contains an entry for this variant (Variation ID: 2604). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 26, 2023 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; One of three frameshift variants in the exon 13 hotspot that accounts for approximately 60% of all pathogenic alleles (Yan et al., 2013); This variant is associated with the following publications: (PMID: 26207694, 22383261, 26335786, 21328543, 28914269, 29801470, 31455396, 31019026, 14508707, 27174544, 23554269) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at